The convergence of healthcare and software engineering is reshaping the life sciences industry. Software is no longer simply a supporting technology; in many cases, it serves as the primary diagnostic or therapeutic component of a medical device. The rapid growth of Software as a Medical Device (SaMD) and AI/ML-enabled technologies has consequently pushed regulators to modernize existing frameworks.

For life sciences companies, understanding these changes is increasingly a strategic necessity. Regulatory requirements now influence product development, engineering processes, quality systems and, ultimately, a company’s ability to bring products to market.

QMSR Brings Greater Global Alignment

A major regulatory development is the FDA’s transition from the long-standing Quality System Regulation (QSR) to the Quality Management System Regulation (QMSR).

The previous QSR, established under 21 CFR Part 820 in 1996, provided the foundation for medical-device design controls in the United States. However, differences between the U.S. framework and international standards such as ISO 13485:2016 created additional complexity for companies operating globally.

The FDA finalized the QMSR rule in January 2024, with the new framework taking effect on February 2, 2026. The regulation incorporates ISO 13485 by reference, moving U.S. requirements toward a more internationally harmonized, risk-based quality-management model.

What the Transition Means for Software as a Medical Device ?

The QMSR introduces several important changes for software developers and manufacturers.

First, traditional U.S. design-control requirements are largely aligned with ISO 13485’s Clause 7.3, reducing the need for separate quality systems across markets. Documentation terminology also changes, with the Medical Device File (MDF) replacing familiar concepts such as the Design History File and Device Master Record.

Risk management becomes even more central. Companies are expected to integrate risk analysis throughout the software lifecycle, with ISO 14971 serving as a key framework for meeting these requirements.

The FDA’s inspection scope is also expanding. Internal audits, supplier audits and management reviews, previously exempt from routine inspection under the QSR, may now face greater regulatory scrutiny.

Making Agile Work Within Regulatory Controls

Another major challenge is reconciling modern Agile development with medical-device regulations. Traditional regulatory processes were often associated with sequential, waterfall-style development, while software teams increasingly rely on iterative sprints and continuous refinement.

Standards such as IEC 62304 provide a pathway for combining Agile engineering with robust documentation, traceability and risk controls. For Software as a Medical Device developers, the goal is no longer choosing between Agile innovation and regulatory compliance, but building development processes that support both.

Read for More Information :- UC Researchers Receive Funding to Address Weight Gain Linked to Bipolar Medication